Can Stryker's Q2 Recovery and Guidance Support a Stronger Second Half?

Stryker Corporation SYK entered the second half of 2026 with momentum restored after the March cybersecurity disruption. Second-quarter sales, earnings and margins improved as production recovered, while management narrowed its full-year outlook.

The next test is execution. Stryker must keep normalizing production, convert elevated backlog into shipments and support a broad product launch cycle. Those factors will determine whether the stronger second half embedded in management’s expectations materializes.

Stryker’s Q2 Recovery Rebuilt Momentum

Stryker reported second-quarter net sales of $6.6 billion, up 9.4% year over year. Organic sales increased 9%, while adjusted earnings rose 17.9% to $3.69 per share.

Profitability improved with the recovery. Adjusted operating margin reached 27.4%, up 170 basis points year over year, as stronger sales, improved gross margin and spending discipline helped offset lingering operating pressures. MedSurg and Neurotechnology grew 9.2% organically, while Orthopaedics advanced 8.6%, showing that the rebound extended across both major businesses.

SYK’s Guidance Sets a High Bar for the Second Half

Management narrowed its 2026 organic sales growth outlook to 8.3%-9.3% and adjusted earnings guidance to $14.95-$15.10 per share. The ranges assume continued recovery execution after the first-quarter disruption rather than a simple continuation of second-quarter catch-up.

The sales outlook includes a modestly positive pricing contribution. Foreign exchange is also expected to have a slightly favorable effect on sales and adjusted earnings if rates remain near current levels. Meeting the guidance therefore depends heavily on operational delivery through the rest of the year.

Stryker Corporation Revenue (Quarterly)

Stryker Corporation revenue-quarterly | Stryker Corporation Quote

Stryker’s Backlog Can Convert Into Growth

Capital demand provides visibility into that second-half opportunity. Stryker exited the quarter with elevated backlog and strong orders, while management expects continued production ramping to support higher deliveries. Mako recorded its best-ever second quarter for installations in both the United States and international markets.

The core question is capacity. Management said the company has the orders to support high growth but must manufacture enough capital equipment to convert demand into reported sales. The competitive robotics backdrop remains active. Zimmer Biomet Holdings, Inc. ZBH recently received U.S. clearance and completed first cases with its next-generation ROSA Shoulder System. Intuitive Surgical, Inc. ISRG is also expanding placements of its da Vinci 5 platform, reinforcing continued hospital interest in robotic-assisted surgery.

SYK Still Carries Cyber and Supply Risks

The recovery still carries costs. Cyber remediation and stabilization spending is expected to continue in the second half, while manufacturing and supply-chain pressures remain part of the margin picture. Those expenses can limit operating leverage even as production normalizes.

Peripheral Vascular is another execution point. A supply disruption created a meaningful U.S. back-order position and lost sales in the second quarter. Management expects those back orders to reach a manageable level by the end of the third quarter, but any slower improvement could affect the cadence of the broader recovery.

Stryker’s Ranking Signals Are Not Provided

The second-half setup is stronger, but it is not automatic. Backlog, capital demand and product activity support the growth case, while production constraints, vascular supply issues and cyber-related costs keep the risk-reward balance measured.

Currently, Stryker carries a Zacks Rank #3 (Hold). Likewise, Zimmer Biomet and Intuitive Surgical also carry a Zacks Rank of 2. The near-term case rests on whether Stryker converts demand into sales while protecting the margin recovery. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research